AstraZeneca's Brilinta: Can Advisory Committee Help Build Momentum?
This article was originally published in The Pink Sheet Daily
Executive Summary
Antiplatelet ticagrelor will likely confront the "North American anomaly" during its July 28 review by FDA's cardio-renal panel.